Toyobo Co., Ltd. (TYOBY)

Ligand Pharmaceuticals Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	30,787	28,581	33,796	60,703	27,176	34,695
Cash & Short-Term Investments	30,787	28,581	33,796	60,703	27,176	34,695
Cash Growth	-3.22%	-15.43%	-44.33%	123.37%	-21.67%	37.42%
Receivables	98,372	105,615	102,327	100,450	101,517	93,755
Inventory	120,657	118,982	121,983	121,901	96,049	76,310
Other Current Assets	12,786	14,317	15,627	16,079	14,572	8,203
Total Current Assets	262,602	267,495	273,733	299,133	239,314	212,963
Property, Plant & Equipment	297,043	296,518	281,475	240,234	227,574	224,640
Long-Term Investments	-	27,327	25,712	23,379	28,130	33,845
Other Intangible Assets	4,971	5,032	4,670	4,633	4,307	4,674
Long-Term Deferred Tax Assets	-	21,427	21,400	21,527	18,449	15,066
Other Long-Term Assets	46,896	-	-	-	-	-
Total Assets	611,512	617,799	606,990	588,906	517,774	491,188
Accounts Payable	42,097	51,825	54,011	58,592	53,202	45,760
Accrued Expenses	-	5,260	5,253	4,776	4,778	4,691
Short-Term Debt	54,922	58,043	68,385	71,595	40,592	40,767
Current Portion of Long-Term Debt	17,829	21,684	28,069	39,472	21,418	20,107
Other Current Liabilities	31,432	23,508	28,430	28,065	26,760	20,119
Total Current Liabilities	146,280	160,320	184,148	202,500	146,750	131,444
Long-Term Debt	192,365	181,343	145,637	114,099	125,681	122,046
Long-Term Deferred Tax Liabilities	18,990	18,990	18,762	19,641	19,641	20,156
Other Long-Term Liabilities	10,880	10,771	12,181	8,578	8,476	10,378
Total Liabilities	382,860	385,755	376,903	367,484	320,625	302,553
Common Stock	51,730	51,730	51,730	51,730	51,730	51,730
Additional Paid-In Capital	32,661	32,661	33,187	32,402	32,193	32,202
Retained Earnings	67,013	68,967	70,315	70,490	74,700	64,351
Treasury Stock	-925	-925	-1,006	-781	-221	-294
Comprehensive Income & Other	42,957	42,879	42,807	35,747	36,474	37,740
Total Common Equity	193,436	195,312	197,033	189,588	194,876	185,729
Minority Interest	35,216	36,732	33,054	31,834	2,273	2,906
Shareholders' Equity	228,652	232,044	230,087	221,422	197,149	188,635
Total Liabilities & Equity	611,512	617,799	606,990	588,906	517,774	491,188
Total Debt	265,116	261,070	242,091	225,166	187,691	182,920
Net Cash (Debt)	-234,329	-232,489	-208,295	-164,463	-160,515	-148,225
Net Cash Per Share	-2657.76	-2637.45	-2364.41	-1850.29	-1806.06	-1668.56
Filing Date Shares Outstanding	88.17	88.17	88.1	88.01	88.9	88.85
Total Common Shares Outstanding	88.17	88.17	88.1	88.33	88.9	88.85
Working Capital	116,322	107,175	89,585	96,633	92,564	81,519
Book Value Per Share	2193.95	2215.11	2236.50	2146.46	2192.17	2090.47
Tangible Book Value	188,465	190,280	192,363	184,955	190,569	181,055
Tangible Book Value Per Share	2137.57	2158.04	2183.49	2094.01	2143.72	2037.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.